Results 191 to 200 of about 202,668 (261)

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang   +10 more
wiley   +1 more source

De‐Escalation of Neoadjuvant Treatment for HER2‐Positive Breast Cancer

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT With improved prognosis in early HER2‐positive breast cancer, safely de‐escalating treatment is increasingly investigated to minimize overtreatment. This article focuses on neoadjuvant de‐escalation strategies for HER2‐positive breast cancer.
Yiyin Ma, Dedian Chen, Sheng Huang
wiley   +1 more source

Defining physician acceptance of radiosensitivity testing for guiding therapeutic interventions in head and neck cancer: A Delphi consensus study. [PDF]

open access: yesClin Transl Radiat Oncol
Thariat J   +13 more
europepmc   +1 more source

Nephroprotective Effect of Black <i>Panax vietnamensis</i> var. <i>fuscidiscus</i> Against Cisplatin Toxicity. [PDF]

open access: yesMolecules
Nguyen HT   +10 more
europepmc   +1 more source

Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma. [PDF]

open access: yesDrug Deliv
Murillo D   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy